排序方式: 共有29条查询结果,搜索用时 31 毫秒
1.
Lazaryan D. S. Sotnikova E. M. Evtushenko N. S. 《Pharmaceutical Chemistry Journal》2003,37(11):614-616
Pharmaceutical Chemistry Journal - 相似文献
2.
Jennifer M. Logue Elisa Zucchetti Christina A. Bachmeier Gabriel S. Krivenko Victoria Larson Daniel Ninh Giovanni Grillo Biwei Cao Jongphil Kim Julio C. Chavez Aliyah Baluch Farhad Khimani Aleksandr Lazaryan Taiga Nishihori Hien D. Liu Javier Pinilla-Ibarz Bijal D. Shah Rawan Faramand Anna E. Coghill Marco L. Davila Bhagirathbhai R. Dholaria Michael D. Jain Frederick L. Locke 《Haematologica》2021,106(4):978
CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with ≥grade 3 neutropenia seen in 21 of 70 (30%) patients at day 30 and persisting in 3 of 31 (9.7%) patients at 1 year. B cells were undetectable in 30 of 34 (88.2%) patients at day 30, but were detected in 11 of 19 (57.9%) at 1 year. Median immunoglobulin G levels levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/mL at 1 year after axi-cel (n=19, range: 33– 269). In total, 23 of 85 (27.1%) patients received intravenous immunoglobulins after axi-cel, and 34 of 85 (40%) received granulocyte-colony stimulating factor. Infections in the first 30 days occurred in 31 of 85 (36.5%) patients, of which 11 of 85 (12.9%) required intravenous antibiotics or hospitalization (“severe”) and were associated with cytokine release syndrome, neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, seven severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T-cell immunosuppression without severe infection. 相似文献
3.
Deepa Jagadeesh MD Navneet S. Majhail MD Yizeng He MS Kwang W. Ahn PhD Carlos Litovich MS Sairah Ahmed MD Mahmoud Aljurf MD Ulrike Bacher MD Sherif M. Badawy MD Nelli Bejanyan MD Mitchell Cairo MD Jan Cerny MD Narendranath Epperla MD Nosha Farhadfar MD César O. Freytes MD Robert Peter Gale MD Bradley Haverkos MD Nasheed Hossain MD David Inwards MD Rammurti T. Kamble MD Vaishalee P. Kenkre MD Hillard M. Lazarus MD Aleksandr Lazaryan MD Lazaros Lekakis MD Matthew Mei MD Hemant S. Murthy MD Alberto Mussetti MD Sunita Nathan MD Taiga Nishihori MD Richard F. Olsson MD Praveen Ramakrishnan Geethakumari MD Bipin N. Savani MD Jean A. Yared MD Timothy S. Fenske MD Mohamed A. Kharfan-Dabaja MD Anna Sureda MD Mehdi Hamadani 《Cancer》2020,126(10):2279-2287
4.
Pharmaceutical Chemistry Journal - 相似文献
5.
6.
Shernan G. Holtan Lin Zhang Todd E. DeFor Nelli Bejanyan Mukta Arora Armin Rashidi Aleksandr Lazaryan Florence Kotiso Bruce R. Blazar John E. Wagner Claudio G. Brunstein Margaret L. MacMillan Daniel J. Weisdorf 《Biology of blood and marrow transplantation》2019,25(9):1884-1889
Graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) represents complete, ideal recovery after allogeneic hematopoietic cell transplantation (HCT). However, as originally proposed, this composite endpoint does not account for the possibility that HCT complications may improve after treatment. To more accurately estimate survival with response to GVHD and relapse after HCT, we developed a dynamic multistate GRFS (dGRFS) model with outcomes data from 949 patients undergoing their first allogeneic HCT for hematologic malignancy at the University of Minnesota. Because some patients were successfully treated for GVHD and relapse, dGRFS was higher than the originally defined time-to-event GRFS at 1 year (37.0 versus 27.6%) through 4 years (37.4% versus 22.2%). Mean survival without failure events was .52 years (95% confidence interval, .45 to .58 year) greater in dGRFS compared with the originally defined GRFS. Patient age (P< .001), disease risk (P < .001), conditioning intensity (P = .007), and donor type (P = .003) all significantly influenced dGRFS. The multistate model of dGRFS closely estimates the continuing and prevalent severe morbidity and mortality of allogeneic HCT. To serve the greater HCT community in more accurately modeling recovery from transplantation, we provide our R code for determination of dGRFS with annotations in Supplementary Materials. 相似文献
7.
Erica Dahl Warlick Todd E. DeFor Nelli Bejanyan Shernan Holtan Margaret MacMillan Bruce R. Blazar Kathryn Dusenbery Mukta Arora Veronika Bachanova Sarah Cooley Aleksandr Lazaryan Philip McGlave Jeffrey S Miller Armin Rashidi Arne Slungaard Gregory Vercellotti Celalettin Ustun Claudio Brunsein Daniel Weisdorf 《Biology of blood and marrow transplantation》2019,25(1):56-62
Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 292 consecutive patients, median age 58 years (range, 19 to 75) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total body irradiation (200 cGy) with or without antithymocyte globulin and cyclosporine and mycophenolate mofetil graft-versus-host disease (GVHD) prophylaxis followed by allogeneic HCT at the University of Minnesota from 2002 to 6. Probability of 5-year overall survival was 78% for patients with indolent non-Hodgkin lymphoma, 53% for chronic myelogenous leukemia, 55% for Hodgkin lymphoma, 40% for acute myelogenous leukemia, 37% for myelodysplastic syndrome, 29% for myeloma, and 14% for myeloproliferative neoplasms. Corresponding outcomes for relapse were 0%, 13%, 53%, 37%, 39%, 75%, and 29%, respectively. Disease risk index (DRI) predicted both survival and relapse with superior survival (64%) and lowest relapse (16%) in those with low risk score compared with 24% survival and 57% relapse in those with high/very-high risk scores. Recipient cytomegalovirus (CMV)-positive serostatus was protective from relapse with the lowest rates in those also receiving a CMV-positive donor graft (29%). The cumulative incidence of 2-year nonrelapse mortality was 26% and was lowest in those receiving a matched sibling graft at 21%, with low (21%) or intermediate (18%) HCT-specific comorbidity index, and was similar across age groups. The incidence of grades II to IV acute GVHD was 43% and grades III to IV 27%; the highest rates were found in those receiving an unrelated donor (URD) peripheral blood stem cell (PBSC) graft, at 50%. Chronic GVHD at 1 year was 36%.Future approaches incorporating alternative GVHD prophylaxis, particularly for URD PBSC grafts, and targeted post-transplant antineoplastic therapies for those with high DRI are indicated to improve these outcomes. 相似文献
8.
Pharmaceutical Chemistry Journal - 相似文献
9.
Lazaryan A Song W Lobashevsky E Tang J Shrestha S Zhang K McNicholl JM Gardner LI Wilson CM Klein RS Rompalo A Mayer K Sobel J Kaslow RA;HIV Epidemiology Research Study Group;Reaching for Excellence in Adolescent Care Health Study Group 《Human immunology》2011,72(4):312-318
Populations of African ancestry continue to account for a disproportionate burden of the human immunodeficiency virus type 1 (HIV-1) epidemic in the United States. We investigated the effects of human leukocyte antigen (HLA) class I markers in association with virologic and immunologic control of HIV-1 infection among 338 HIV-1 subtype B-infected African Americans in 2 cohorts: Reaching for Excellence in Adolescent Care and Health (REACH) and HIV Epidemiology Research Study (HERS). One-year treatment-free interval measurements of HIV-1 RNA viral loads and CD4(+) T cells were examined both separately and combined to represent 3 categories of HIV-1 disease control (76 controllers, 169 intermediates, and 93 noncontrollers). Certain previously or newly implicated HLA class I alleles (A*32, A*36, A*74, B*14, B*1510, B*3501, B*45, B*53, B*57, Cw*04, Cw*08, Cw*12, and Cw*18) were associated with 1 or more of the endpoints in univariate analyses. After multivariable adjustments for other genetic and nongenetic risk factors of HIV-1 progression, the subset of alleles more strongly or consistently associated with HIV-1 disease control included A*32, A*74, B*14, B*45, B*53, B*57, and Cw*08. Carriage of infrequent HLA-B but not HLA-A alleles was associated with more favorable disease outcomes. Certain HLA class I associations with control of HIV-1 infection cross the boundaries of race and viral subtype, whereas others appear confined within one or the other of those boundaries. 相似文献
10.
Richard Kim Raymond Tsao Ann Tan Mike Byrne Khaldoun Almhanna Aleksander Lazaryan Paul Elson Robert J Pelley 《Journal of gastrointestinal surgery》2010,14(7):1159-1169